March 05, 03,2025, Biocon Limited stock price increased by around 4% to reach ₹ 324.50 per share.

 March 05, 03,2025, Biocon Limited stock price increased by around 4% to reach ₹ 324.50 per share.

Biocon Stock Market: Shares of pharmaceutical company Biocon witnessed a surge in demand on Wednesday, March 5, 2025, when they surged 3.08 per cent to hit a high of Rs 324.50 per share. Biocon stock surged after the company's wholly-owned subsidiary Biocon Medicines announced the final approval meeting for Lenalidomide capsules and Dasatinib tablets.

Biocon announced in a return filing. Lenalidomide tablets are available in dosages of 2.5mg, 5mg, 10mg, 15mg, 20mg and 25mg. This medicine is used to treat a number of diseases in the viral, including multiple myeloma, mantle cell lymphoma, follicular ultrastrate lymphoma, marginal zone lymphoma and myelodysplastic syndrome (MDS)-related compounds.

Dasatinib tablets are available in different dosages with variants of 20 diopters, 50 diopters, 70 diopters, 80 diopters, 100 diopters and 140 diopters. This medicine is used to treat Philadelphia chroma-like chronic myeloid leukemia (Ph +CML) for the treatment of children 1 year of age or older. Philadelphia chromatinib in lactic acid of dasatinib is also used to treat chromium chloride leukemia (Ph +CML) and Philadelphia chromatoplasmic monooxygenase leukemia (Ph +ALL) when other treatments, such as imatinib, are not effective. Additionally, it can be used with chemotherapy in children 1 year and older with newly diagnosed Ph +ALL.

Biocon Drug has also received a prototype version under Adena for its Rivaroxaban Tablet USP, available in 2.5 doses, 10 doses, 15 doses, and 20 doses. This information was shared by Biocon in a statement.

Rivaroxiban is used to treat severe venous thrombosis, pulmonary embolism, and to measure the strength of stroke and systemic embolism in patients with nonvalvular atrial fibrillation dialysis.

Biocon said in a press release that these ideas further enhance their portfolio of manufactured, complex drug laptops.

About Biocon

Biocon is a leading global biotechnology company focused on the development and production of laboratories. It comprises various business lines including biosimilars, research materials, generics and innovative biologicals.

The company has a portfolio of 20 biosimilars through Biocon Biologics, its biosimilar arm, primarily targeting key areas such as oncology, immunology and diabetes. Biocon has a strong position in the biologics market, especially in the advanced stage, and has a pipeline of over 20 volumes with launches expected by 2030.

Another essential division of the company is Synagene, its independent research services arm. Synagene Pharmaceuticals provides a wide range of research, development and manufacturing facilities in various sectors such as pharmaceuticals, biotechnology and consumer goods. This division makes a significant contribution to Biocon's overall growth and innovation.

In the generics sector, Biocon specializes in the production of Activation Medicinal Ingredients (APIs), which include more than 50 different formulations with high potency gasoline.

In addition, Biocon has achieved significant milestones in novel biologics, including the development of India's first indigenously manufactured monoclonal antibody, nimotuzumab, and the biologic itolizumab for the treatment of psoriasis. Biocon continues to expand internationally, including through recent investments such as the US oral solid dose facility and biologics manufacturing facility at Syngene. These acquisitions support Biocon's continued growth and ability to serve international markets. As of 11:55 am, Biocon's stock was up 1.37%, trading at Rs 319.10 per share. This outperformed the stock, which was up 1.08% at Rs 73,777.40.